Elekta Ab Stock Price, News & Analysis
Company Description
Elekta Ab (OTC Link: EKTAY) is a publicly traded medical devices company in the Healthcare sector. The company has a market capitalization of $1.9B.
EKTAY stock has gained 11.1% over the past year. Shares last traded at $5.80.
This page provides a comprehensive overview of EKTAY stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Elekta Ab (EKTAY) stock last traded at $5.80. Over the past 12 months, the stock has gained 11.1%. At a market capitalization of $1.9B, EKTAY is classified as a small-cap stock with approximately 367.1M shares outstanding.
Latest News
Elekta Ab has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings. View all EKTAY news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Elekta Ab (EKTAY) currently stands at 4.5 thousand shares, up 253.8% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 55.1%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Elekta Ab (EKTAY) currently stands at 1.6 days, up 57% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has increased 57% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.2 days.
EKTAY Company Profile & Sector Positioning
Elekta Ab (EKTAY) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing EKTAY often look at related companies in the same sector, including Elekta Ab (EKTAF), Nolato (NLTBF), Draegerwerk (DGWPF), Kuros Bioscience (CSBTF), and Vitrolife (VTRLY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate EKTAY's relative position within its industry.